Delving into the Latest Updates on Vatelizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

+ [4]

Target

CD49b

Mechanism

CD49b inhibitors(integrin subunit alpha 2 inhibitors), Immunosuppressants

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication

Colitis, UlcerativeMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting+ [3]

Originator Organization

Glenmark Pharmaceuticals Ltd.

Active Organization

NMS Group SpA

Glenmark Pharmaceuticals Ltd.

Inactive Organization

Genzyme Corp.

Sanofi

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 142086L

Source: *****

Sequence Code 142094H

Source: *****

Primary Objectives:
To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in new contrast-enhancing lesions (CELs) in relapsing remitting multiple sclerosis (RRMS) patients.
To evaluate multiple doses of vatelizumab for a dose-response.
Secondary Objectives:
To evaluate the safety and tolerability of vatelizumab compared to placebo.
To evaluate the pharmacokinetics (PK) of vatelizumab.

Start Date01 Sep 2014

Sponsor / Collaborator

Genzyme Corp.

NCT01861249 / TerminatedPhase 2

A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Primary Objective:
To assess the long term safety and tolerability of SAR339658
Secondary Objective:
To assess the long term efficacy of SAR339658

Start Date01 Jul 2013

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Vatelizumab

Login to view more data

100 Translational Medicine associated with Vatelizumab

Login to view more data

100 Patents (Medical) associated with Vatelizumab

Login to view more data

2

Literatures (Medical) associated with Vatelizumab

21 May 2019·International ImmunologyQ3 · MEDICINE

VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells

Q3 · MEDICINE

Article

Author: Klotz, Luisa ; Breuer, Johanna ; Schneider-Hohendorf, Tilman ; Schwab, Nicholas ; Wiendl, Heinz ; Antonijevic, Irina ; Rakhade, Sanjay ; Herich, Sebastian ; Ostkamp, Patrick

AbstractIntegrin α2β1, also known as very late antigen (VLA)-2, is a collagen-binding molecule expressed constitutively on platelets. Vatelizumab, a monoclonal antibody targeting the α2 subunit (CD49b) of VLA-2, was recently investigated for its safety and efficacy during a Phase 2 clinical study in multiple sclerosis patients, as integrin-mediated collagen binding at the site of inflammation is central to a number of downstream pro-inflammatory events. In the course of this study, we could show that VLA-2 is expressed ex vivo on platelets, platelet–T-cell aggregates, as well as a small population of highly activated memory T cells. Even though the clinical trial did not meet its primary clinical end-point (reduction in the cumulative number of new contrast-enhancing lesions on magnetic resonance imaging (MRI)), we observed enhanced frequencies of regulatory T cells (TREG) following vatelizumab treatment. Elevated TREG frequencies might be explained by the inhibition of p38 mitogen-activated protein kinase (MAPK) signaling, which is critically involved in the polarization of T helper 17 (TH17) cells and is activated by the α2 integrin cytoplasmic domain. Our findings suggest that blockade of VLA-2 might be a way to safely shift the TH17/TREG balance by inducing TREGin vivo.

03 Jul 2015·Expert Opinion on Investigational DrugsQ2 · MEDICINE

Inflammatory bowel disease therapies discontinued between 2009 and 2014

Q2 · MEDICINE

Review

Author: Nikfar, Shekoufeh ; Mozaffari, Shilan ; Abdollahi, Mohammad

INTRODUCTIONNew therapeutic approaches are currently under development, which consider the fundamental mechanisms involved in the pathogenesis of inflammatory bowel disease (IBD). The disease is associated with inflamed intestinal and colonic mucosa in response to the dysregulated immune system.AREAS COVEREDThe aim of this article is to review drugs that have been designed for the treatment of IBD and discontinued between 2009 and 2014. Herein, nine molecules with different mechanisms of action are under review. Brodalumab, daclizumab, elubrixin and vatelizumab were withdrawn from the Phase II trial due to the lack of efficacy. Abatacept was not significantly superior to the placebo in the rate of remission and its Phase III trials were stopped. CNDO-210 and Catridecacog were discontinued due to safety concerns and lack of efficacy, respectively. Finally, NU-206 and alkaline phosphatase also ceased in development during Phase I and II tests.EXPERT OPINIONThe development in our knowledge and understanding of the pathophysiology of IBD and the identification of key objectives for the future play significant roles in IBD therapeutic development. Furthermore, well-planned clinical trials with concise measures of efficacy and safety are required to better decide whether to extend or terminate the development process. Some anti-inflammatory cytokines such as IL-2, IL-12, IL-17, IL-18, IL-23 and INF-γ could garner more attention in the future.

1

News (Medical) associated with Vatelizumab

25 Sep 2006

·www.biospace.com

Chromos Molecular Systems Inc. Announces Changes To Its Board Of Directors

BURNABY, BC, Sept. 22 /PRNewswire-FirstCall/ - Chromos Molecular Systems Inc. today announced that Dr. James Miller and Mr. Ronald MacKenzie have resigned from its Board of Directors, effective immediately. Chromos is currently in discussions with various groups, included those affiliated with Dr. Miller and Mr. MacKenzie, regarding additional financing. Acting on advice from their respective legal counsel, Dr. Miller and Mr. MacKenzie indicated that they have tendered their resignations as directors to avoid any potential conflict of interest in financing discussions. These resignations bring the number of directors on the Board to four. In its Management's Discussion and Analysis of Financial Condition and Results of Operations for the second quarter ended June 30, 2006, Chromos reported that its funds on hand and anticipated revenues from existing licensing contracts would be sufficient to fund its operations into the fourth quarter of 2006. There can be no assurance that additional financing will be available at all or on acceptable terms to permit the Company's current operations to continue. Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders. The Company's lead program, CHR-1103, is a humanized monoclonal antibody being developed as a treatment for acute relapses associated with multiple sclerosis. Chromos generates revenue from its proprietary ACE System technology to engineer production quality cell lines to manufacture biopharmaceutical products including monoclonal antibodies. For more information visit our website at . Risks and Uncertainties Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Chromos (the "Company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. To the extent possible, management implements strategies to reduce or mitigate the risks and uncertainties associated with the Company's operations. Operating risks include (i) the continued availability of capital to finance the Company's activities; (ii) the Company's limited cash position, (iii) the ability to successfully obtain proof of the effectiveness of the Company's technology (iv) the ability to complete and maintain corporate alliances relating to the development and commercialization of the Company's technology; (v) the ability to obtain and enforce patent and other intellectual property protection for the Company's technology; (vi) market acceptance of the Company's technology; (vii) the competitive environment and impact of technological change; (viii) the Company's ability to attract and retain employees to carry out its business plans and (ix) the timely development and commercialization of any technology or products that are contingent on the completion and maintenance of corporate alliances with third parties. Further details on Chromos' operating risks can be found in the Company's Quarterly and Annual Reports to Shareholders. Chromos is a registered trademark of Chromos Molecular Systems Inc. CONTACT: Jeff Charpentier, Vice President, Finance and Chief Financial Officer, Tel: (604) 415-7132, Email:jcharpentier@chromos.com, Website: Chromos Molecular Systems Inc. CONTACT: Jeff Charpentier, Vice President, Finance and Chief FinancialOfficer, Tel: (604) 415-7132, Email:jcharpentier@chromos.com, Website:

AntibodyExecutive Change

100 Deals associated with Vatelizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Vatelizumab	-	DB12346

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	Phase 1	US	Genzyme Corp.	01 Sep 2014
Multiple Sclerosis, Relapsing-Remitting	Phase 1	CA	Genzyme Corp.	01 Sep 2014
Colitis, Ulcerative	Discovery	AT	Sanofi	01 Aug 2012
Colitis, Ulcerative	Discovery	US	Sanofi	01 Aug 2012
Colitis, Ulcerative	Discovery	PL	Sanofi	01 Aug 2012
Colitis, Ulcerative	Discovery	IT	Sanofi	01 Aug 2012
Colitis, Ulcerative	Discovery	FR	Sanofi	01 Aug 2012
Colitis, Ulcerative	Discovery	DE	Sanofi	01 Aug 2012
Colitis, Ulcerative	Discovery	CA	Sanofi	01 Aug 2012
Multiple Sclerosis	Discovery	-	Glenmark Pharmaceuticals Ltd.	-